INBX (Inhibrx Biosciences) Accounts Receivable : $0.46 Mil (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Inhibrx Biosciences Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Inhibrx Biosciences's accounts receivables for the quarter that ended in Sep. 2024 was $0.46 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Inhibrx Biosciences's Net-Net Working Capital per share for the quarter that ended in Sep. 2024 was $10.54.

Inhibrx Biosciences Accounts Receivable Historical Data

The historical data trend for Inhibrx Biosciences's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibrx Biosciences Accounts Receivable Chart

Inhibrx Biosciences Annual Data

Trend

Dec22

Dec23

Accounts Receivable

0.24

0.78

Inhibrx Biosciences Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Accounts Receivable	Get a 7-Day Free Trial			-	0.78	0.17	0.27	0.46

Inhibrx Biosciences Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Inhibrx Biosciences Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Inhibrx Biosciences's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.455	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Inhibrx Biosciences's accounts receivable are only considered to be worth 75% of book value:

Inhibrx Biosciences's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(196.332	+	0.75 * 0.455	+	0.5 * 0	-	44.095
-	0	-	0)	/	14.476
=	10.54

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Inhibrx Biosciences Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Inhibrx Biosciences's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibrx Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Biosciences Inc (NAS:INBX) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

11025 N. Torrey Pines Road, Suite 140, La Jolla, CA, USA, 92037

Website

https://www.inhibrx.com

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.